The American College of Rheumatology (ACR) 2024 Convergence has just concluded, showcasing significant advancements and ...

GlaxoSmithKline’s Benlysta has been on the market for almost a decade, but it still has some tricks up its sleeve – it’s just become the first and only FDA-approved treatment for lupus ...

All other infusion-related and hypersensitivity reactions were mild or moderate. Covid-19 monoclonal antibodies are needed to protect immunocompromised persons who may not mount an adequate ...

Most people with scleroderma have autoantibodies. Several scleroderma-specific antibodies have been identified. These can help with diagnosis and give insight into the type of disease you may ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

GSK was the first to market when its BLyS-specific inhibitor Benlysta was approved by the FDA in 2011. It has since become a blockbuster medicine, while AstraZeneca’s more recent challenger ...

In a new study, researchers examined four randomized controlled trials of belimumab (Benlysta®) to gain a better understanding of systemic lupus erythematosus (SLE) active disease progression with the ...

It is notoriously hard to treat effectively. Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to ...

And they don’t need any exotic manufacturing methods — if you can produce proteins and antibodies at scale, you can probably make AbCs too. The $20 million round was led by Madrona Ventures ...

"Most therapeutic antibodies target a single viral site and lose effectiveness within a year as new variants appear. AMETA, however, is designed to bind to multiple conserved regions of the virus ...